# Pieter Sonneveld

Source: https://onco.cc/people/pieter-sonneveld/  
OnCo record `pieter-sonneveld` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led PERSEUS, which established daratumumab-VRd as the standard for transplant-eligible myeloma.

## Summary

Pieter Sonneveld was principal investigator of PERSEUS, the trial showing daratumumab added to bortezomib-lenalidomide-dexamethasone before and after transplant improves progression-free survival and MRD negativity in newly diagnosed myeloma, and led the HOVON-65/GMMG-HD4 trial that established bortezomib in induction. He chairs the European Myeloma Network and has led HOVON myeloma trials for three decades.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; transplant; hovon
- Role: Professor of Hematology, Erasmus MC Cancer Institute; Chair, European Myeloma Network
- Specialisms: Multiple myeloma; Transplant-eligible myeloma; Daratumumab quadruplets; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Sonneveld%20P%5BAuthor%5D%20myeloma%20daratumumab%20PERSEUS

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [CD38](https://onco.cc/targets/cd38/)
- companies: [HOVON](https://onco.cc/companies/hovon/)
- institutions: [Erasmus MC Cancer Institute](https://onco.cc/institutions/erasmus-mc/)
- trials: [PERSEUS](https://onco.cc/trials/perseus/)
- key papers: [PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma](https://onco.cc/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/pieter-sonneveld.json